AccuPulse PFA System Successfully Deployed in First-Ever Clinical Application at Beijing Anzhen Hospital, Capital Medical University

Recently,Beijing Anzhen Hospital, Capital Medical UniversityAs one of the first clinical application units in China for AccuPulse's cardiac pulse ablation system,Professor Long Deyong's TeamDr. Li MengmengUnder the leadership of, successfully used AccuPulse^®Single-use Cardiac Pulsed Field Ablation Catheter and AccuBlator^®The cardiac pulsed electric field ablation system completed a paroxysmal atrial fibrillation pulsed electric field ablation (PFA) surgery.

Schematic Diagram of Substrate Mapping Before Ablation

Dr. Li Mengmeng commented after the surgery: "The catheter operation during the entire ablation process was very smooth, with complete pulmonary vein isolation achieved, and the operation time was significantly reduced. We are highly satisfied with the use of the AccuPulse Cardiac Pulse Ablation System this time. The circular adjustable loop design allows us to perform mapping and ablation in one step, greatly simplifying the surgical procedure. Particularly, the intuitive real-time contact indication function ensures more precise ablation sites, enhancing the safety of the surgery."

Flexible Adaptation, Precise Contact:Its unique 7.5F adjustable loop diameter design can flexibly match the pulmonary vein anatomy of different patients, achieving personalized adaptation and significantly enhancing the adaptability and safety of the operation.

Intelligent docking, real-time feedback:The system is equipped with AccuPulse's independently developed impedance contact prompting technology, which can monitor the catheter-tissue contact quality in real time, clearly indicate the contact status, assist operators in achieving stable and reliable catheter manipulation, and provide a solid guarantee for precise ablation.

Efficient Integration, Streamlined Processes:The circular catheter integrates mapping, modeling, and ablation functions, rapidly constructing a three-dimensional electroanatomical model of the heart during surgery, precisely locating lesions, and significantly reducing reliance on additional high-density mapping catheters in traditional surgeries. This not only decreases surgical complexity but also saves on consumable costs, providing atrial fibrillation patients with a safer, more effective, and less invasive treatment option.

AccuPulse's disposable cardiac pulsed field ablation catheter has been approved, overcoming the challenges of stability and anatomical adaptability in PFA ablation catheters, providing a precise and reliable solution for pulmonary vein isolation (PVI). AccuPulseThe unique 7.5F adjustable loop diameter design of the AccuPulse cardiac pulsed field ablation catheter allows for flexible adaptation to pulmonary vein ablations in different anatomical structures. Intelligent contact sensing and flexible electrode selection provide operators with complete control, enabling precise pulsed field ablation!

Safer:7.5F Ultra-thin Catheter, Reducing Tissue Damage

More Stable:Smart Snap Tips for More Precise Operation

AccuPulse Medical Technology Co., Ltd. is an innovative enterprise based in Suzhou that focuses on the research, development, and industrialization of cutting-edge technologies in the field of cardiac electrophysiology. The company’s core team possesses extensive expertise in electrophysiological technology and substantial experience in the industrialization of medical devices, consistently striving to provide safer, more efficient, and more convenient treatment options for patients with arrhythmias such as atrial fibrillation.

This time, AccuPulse^®Single-use Cardiac Pulsed Field Ablation Catheter and AccuBlator^®The successful application of the cardiac pulsed electric field ablation system at Beijing Anzhen Hospital, Capital Medical University, marks a milestone achievement for AccuPulse in the field of innovative electrophysiological treatment technology.

Since its establishment in 1983, the Arrhythmia Center of Beijing Anzhen Hospital, Capital Medical University, has been dedicated to the diagnosis, treatment, and scientific exploration of arrhythmias. After more than four decades of relentless efforts, the center has risen to become a global leader in the field of arrhythmia. Under the leadership of Professor Ma Changsheng and the center's director, Professor Long Deyong, the center has gained high recognition from the international medical community for its outstanding academic achievements and clinical expertise. Whether in the innovation of treatment technologies or the in-depth research on complex conditions such as chronic atrial fibrillation and ventricular tachycardia, the center has demonstrated its prominent status and far-reaching influence on the international stage.

The Arrhythmia Center has achieved remarkable scientific research results, publishing over 300 academic papers in top journals such as Circulation and JACC, with research findings cited by international guidelines and textbooks. The center has established the highest-quality, largest-scale, and most representative atrial fibrillation registry study (CAFR) in China, influencing the development of international guidelines. Additionally, the center has undertaken more than forty national-level scientific research projects, including sixteen projects under the 2030, 863, and 973 plans, extensively conducting electrophysiological mechanism and clinical research on arrhythmias, promoting the application of artificial intelligence in diagnosis and treatment, and further solidifying its leading position in innovative medical technology.

M.D., Ph.D., Postdoctoral Fellow, Chief Physician, Professor, Doctoral Supervisor. Executive Director of the Arrhythmia Center at Beijing Anzhen Hospital, Capital Medical University, and the National Clinical Research Center for Cardiovascular Diseases. Deputy Chairman of the Youth Committee of the Cardiovascular Branch of the Chinese Medical Association. Standing Committee Member and Secretary General of the Chinese Heart Rhythm Society; Member of the Expert Committee on Arrhythmia Interventional Treatment of the National Health Commission; Mentor of the "National Arrhythmia Treatment Standards and New Technology Training" program by the Chinese Medical Doctor Association; Academic Mentor of Beijing's "Young Talent" Cultivation Plan; Teaching Mentor of the "Western Light" Program by the Organization Department of the CPC Central Committee.

M.D., Attending Physician at the Arrhythmia Center of Beijing Anzhen Hospital, Capital Medical University, and Secretary of the Ventricular Arrhythmia Group of the Chinese Heart Rhythm Society. Main research focus includes the electrophysiological mechanisms of complex arrhythmias and the development of innovative medical devices. As the first author, published 12 SCI papers in leading journals such as "Heart Rhythm" and "Europace". Contributed to 10 book publications. Holds 8 patents for innovative treatments of refractory arrhythmias, with a total transformation value of 600,000 yuan. Principal investigator of one "14th Five-Year Plan" Ministry of Science and Technology Youth Cultivation Project and one National Natural Science Foundation Youth Fund project. Secretary of the Ventricular Arrhythmia Group of the Chinese Heart Rhythm Society. Young Editorial Board Member and Reviewer of the journal "Circulation AE", and Young Editorial Board Member of the journal "Cardiovascular Innovations and Applications (CVIA)".